Anavex Life Sciences Corp (AVXL)

[TTTav66]

Anavex Life Sciences Corp. will be in attendance at The New York Academy Of Sciences day-long symposium, Neuro-Immunology: The Impact of Immune Function on Alzheimer's Disease, Tuesday, September 25.
https://www.nyas.org/events/2018/neuro-immunology-the-impact-of-immune-function-on-alzheimer-s-disease/?tab=attendees

And a reminder of the rest of the week:

Sept. 26 : CNS AND NEURODEGENERATIVE TARGETS - DISCOVERY ON TARGET - Boston, MA

1:50 Chairperson’s Remarks
- Daniel Klamer, PhD, MBA, Vice President, Business Development & Scientific Strategy, Anavex Life Sciences Corp.

1:55 ANAVEX 2-73, a Sigma-1 Receptor Agonist, in Phase IIb/III for the Treatment of Alzheimer’s Disease
- Daniel Klamer, PhD, MBA, Vice President, Business Development & Scientific Strategy, Anavex Life Sciences Corp.
Anavex Life Sciences Corp.’s lead drug candidate, ANAVEX 2-73, recently completed a successful Phase IIa clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by activating the sigma-1 receptor. Full genomic analysis of the study participants resulted in the identification of genetic mutations linked to treatment response. Clinical studies in several indications are planned or underway utilizing a precision medicine approach.
http://www.discoveryontarget.com/CNS-Neurodegenerative-Targets/

5:05 Breakout Discussion Group: The Use of Precision Medicine in Drug Development for CNS Disorders
- Moderator: Daniel Klamer, PhD, MBA, Vice President, Business Development & Scientific Strategy, Anavex Life Sciences Corp.
• What questions should be asked before adding a new biomarker to your clinical trial?
• What lessons can we learn from oncology?
• Pros and cons using biomarkers as surrogate endpoints
https://www.discoveryontarget.com/breakout-discussions

--------

Sept. 27 : NON-OPIOD PAIN DRUG DEVELOPMENT SUMMIT - Boston, MA

2:30 Case Study: ANAVEX®1066, a Sigma-1 Receptor Antagonist, as a Therapeutic Candidate for Pain
- Daniel Klamer : VP, Business Development & Scientific Strategy, Anavex Life Sciences Corp.
• Strong scientific rational for the use of Sigma-1 Receptor antagonists in pain
• ANAVEX®1066 have demonstrated efficacy in several different pain models
• ANAVEX®1066 is safe in doses exceeding the observed efficacious ranges
http://www.non-opioiddrugdevelopment.com/